MGMT and glioblastoma: Another molecular event with clinical importance is the epigenetic deactivation of MGMT—through promoter methylation—a predictor of a higher benefit of TMZ, an alkylating agent, in GBM patients [2], as the MGMT gene encodes a protein with DNA repair capabilities that functions to remove alkyl groups from the O6 position of guanine [9].